FDA Delays Final OK for Type 2 Drug Empagliflozin
The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at
Read MoreThe FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at
Read MoreThe U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a
Read MoreA total of 182 new drugs to treat diabetes or diabetes-related conditions are currently in clinical trials or undergoing review
Read MoreThe U.S. Food and Drug Administration has approved the expanded use of the Dexcom G4 Platinum Continuous Glucose Monitoring System
Read MoreThe Food and Drug Administration is proposing separate guidelines for over-the-counter blood glucose meters compared to those used at the
Read MoreDV-100, a drug designed to halt the body’s autoimmune attack on pancreatic beta cells that leads to type 1 disease,
Read MoreThe Food and Drug Adminsitration, reversing itself on a decision it made in October, has opened the way for a
Read MoreThe non-profit consumer action group Citizens for Health earlier this month called on the Food and Drug Administration to do
Read MoreThe U.S. Food and Drug Administration has granted 510(k) clearance for the NovoPen Echo®, the first insulin injection device on
Read MoreThe U.S. Food and Drug Administration has announced that it has issued letters warning 15 U.S. and foreign companies to
Read MoreA new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works
Read More